



BioAegis Therapeutics Named New Jersey's Most Valuable Venture-Backed Company Led by a Woman

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) -- BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics' accolade was based on 2019 PitchBook data. Dr. Susan Levinson co-founded BioAegis in 2011 and has been its CEO since its inception.

Details about the PitchBook rankings:

[BioAegis Therapeutics: PitchBook Profile](#)

[PitchBook Awards by State](#)

Dr. Susan Levinson, CEO and Co-Founder

Dr. Susan Levinson has over 30 years of life sciences consulting and pharmaceutical experience spanning the entire value chain, from the lab bench to marketing. Most of her career was at Novartis Pharmaceuticals where she held executive positions in Business Strategy and Marketing Planning. Susan began her career in Research. As a Principal Scientist, she managed drug discovery programs at Ortho Pharmaceutical. Susan has a B.S in Biochemistry from the University of Wisconsin and a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine.

Defying the Gender Funding Gap

Many women-run businesses still face funding challenges. According to PitchBook, "Last year (2018), companies founded solely by women garnered 2.3% of the total capital invested in venture-backed startups in the US last year." Susan Levinson agrees, *"The gender gap in venture capital is real, but BioAegis' mission to save lives and improve outcomes in inflammatory disease drives our commitment. Our disruptive technology promises to make this possible."*

About BioAegis Therapeutics

BioAegis Therapeutics is capitalizing on new discoveries about gelsolin — a key component of the body's immune system that offers a new paradigm for the treatment of diseases driven by inflammation and infection.

Gelsolin fills a major gap in the current treatment of inflammatory disease — by controlling excess inflammation without suppressing the immune response to threats. In addition, recent remarkable findings demonstrate gelsolin's ability **to make ineffective antibiotics work again** addressing antibiotic resistance.

In August 2019, BioAegis successfully completed a Phase 1b/2a Community-Acquired Pneumonia clinical trial. BioAegis now is fundraising for its phase 2b trial in severe pneumonia. This study is designed to demonstrate gelsolin repletion reduces morbidity and mortality in severe pneumonia patients, a group that is at high risk for mortality.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For more information:

Contact: Steven Cordovano,
BioAegis Phone: 203-952-6373
Email: scordovano@bioaegistx.com